•   
  •   
  •   

News Moderna increases sales significantly - Moderna share increases

17:58  25 february  2021
17:58  25 february  2021 Source:   finanzen.net

Stock exchange trading on Wednesday: 10 important facts

 Stock exchange trading on Wednesday: 10 important facts These 10 facts should cause movement in the markets today. © Provided by Finanz.net DANIEL ROLAND / AFP / Getty Images Keep an eye on the entire current trading day here. 1. DAX expected little change The DAX should start Wednesday trading with a minimal minus. Pre-market indications show it 0.05 percent lower at 14,057 points. The US bond yields, which have now risen significantly, are now starting to saw their nerves, experts said unanimously. 2.

The US vaccine manufacturer Moderna published its balance sheet before the US stock market launch.

DANIEL ROLAND/AFP/Getty Images © Provided by Finanz.net DANIEL ROLAND / AFP / Getty Images

For Moderna things went worse in the fourth quarter than a year ago. Per share was still a loss of -0.69 US dollars, this was higher than in the same quarter of the previous year (-0.37 US dollars) after analysts had forecast a loss per share of 0.343 US dollars.

Sales were put at 570.7 million US dollars (same period last year: 14.1 million US dollars), experts had previously assumed sales of 279.4 million US dollars.

In the year as a whole, the group posted a loss of 1.96 US dollars per share, in the previous year the minus had only been 1.55 US dollars per share. Revenues for the year were $ 803.4 million compared to $ 60.2 million in 2019. Analyst estimates were $ 534.9 million at this point.

Covid-19: the EU launches the Hera program to speed up vaccination

 Covid-19: the EU launches the Hera program to speed up vaccination © AP - Aris Oikonomou The President of the European Commission Ursula von der Leyen, during a press conference in Brussels, on February 17, 2021. The European Commission launched this Wednesday, February 17, its Hera Incubator program, a rapid response health agency to fight against the slowness of vaccination campaigns and deal with new variants of Covid-19.

High research and development costs kept the US vaccine manufacturer Moderna in the red at the end of the year, but the strong demand for the corona vaccine is causing sales to explode. This year growth should only really take off. "This is just the beginning," announced Moderna's CEO Stéphane Bancel when the balance sheet was presented in Cambridge, Massachusetts.

Moderna expects revenues of 18.4 billion dollars from its corona vaccine for 2021 based on its sales agreements that have already been made. This puts the biotech group ahead of the US pharmaceutical giant Pfizer , which is assuming annual sales of around 15 billion dollars for its vaccine developed jointly with the German BioNTech .

Moderna was founded in 2010 and went public at the end of 2018. The vaccine boom has seen the stock rise 450 percent over the past twelve months, but so far there have only been losses. In 2020, the total fell by $ 747.1 million. For the Moderna share, the NASDAQ temporarily rose 6.07 percent to $ 153.58. Editor finanzen.net / dpa-AFX

Coronavirus: Austria and Denmark join forces with Israel to boost vaccine production .
© AMIR COHEN CORONAVIRUS: AUSTRIA AND DENMARK PARTNER IN ISRAEL TO BOOST VACCINE PRODUCTION Frustrated by the slowness of their deployment within the European Union, Austria and Denmark have decided to work with Israel to produce second-generation vaccines against the variants of the SARS-CoV-2 coronavirus, outside the system set up by the community bloc.

usr: 0
This is interesting!